Cipla is currently trading at Rs. 581.75, up by 8.50 points or 1.48% from its previous closing of Rs. 573.25 on the BSE.
The scrip opened at Rs. 581.50 and has touched a high and low of Rs. 582.00 and Rs. 567.90 respectively. So far 87080 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 617.70 on 23-Sep-2016 and a 52 week low of Rs. 458.25 on 25-May-2016.
Last one week high and low of the scrip stood at Rs. 590.00 and Rs. 566.55 respectively. The current market cap of the company is Rs. 46697.28 crore.
The promoters holding in the company stood at 37.49%, while Institutions and Non-Institutions held 35.64% and 26.87% respectively.
Cipla’s wholly owned subsidiary - Goldencross Pharma has completed the sale of its 100% equity stake in Four M Propack, India (Four M Propack) to Shriji Polymers (India) (Shriji Polymers). Consequently, Four M Propack ceases to be a subsidiary of GoldenCross with effect from February 01, 2017.
Earlier in January, Goldencross Pharma had entered in to a definitive agreement to sell its 100% equity stake in Four M Propack to Shriji Polymers for a consideration of Rs 13.5 crore and an additional sum derived on the basis of the value of mutual funds, cash and bank balance, tax refunds, etc. at the time of closing estimated at around Rs 5.7 crore.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.